SMY

(2R)-3-(1H-indol-3-yl)-1-{4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-1-oxopropan-2-amine

Created:	2010-09-20
Last modified:	2011-06-04

Find Related PDB Entry
2 entries where SMY is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	56
Chiral Atom Count	2
Bond Count	60
Aromatic Bond Count	16

2D diagram of SMY

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2R)-3-(1H-indol-3-yl)-1-{4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-1-oxopropan-2-amine
Systematic Name (OpenEye OEToolkits)	(2R)-2-azanyl-3-(1H-indol-3-yl)-1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]propan-1-one
Formula	C₂₂ H₂₆ N₆ O S
Molecular Weight	422.546
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=C(N3CCN(c1ncnc2c1C(SC2)C)CC3)C(N)Cc5c4ccccc4nc5
SMILES	CACTVS	3.370	C[CH]1SCc2ncnc(N3CCN(CC3)C(=O)[CH](N)Cc4c[nH]c5ccccc45)c12
SMILES	OpenEye OEToolkits	1.7.0	CC1c2c(ncnc2N3CCN(CC3)C(=O)C(Cc4c[nH]c5c4cccc5)N)CS1
Canonical SMILES	CACTVS	3.370	C[C@@H]1SCc2ncnc(N3CCN(CC3)C(=O)[C@H](N)Cc4c[nH]c5ccccc45)c12
Canonical SMILES	OpenEye OEToolkits	1.7.0	C[C@H]1c2c(ncnc2N3CCN(CC3)C(=O)[C@@H](Cc4c[nH]c5c4cccc5)N)CS1
InChI	InChI	1.03	InChI=1S/C22H26N6OS/c1-14-20-19(12-30-14)25-13-26-21(20)27-6-8-28(9-7-27)22(29)17(23)10-15-11-24-18-5-3-2-4-16(15)18/h2-5,11,13-14,17,24H,6-10,12,23H2,1H3/t14-,17+/m0/s1
InChIKey	InChI	1.03	JGLUXTFIRPYAQV-WMLDXEAASA-N

Related Resource References

Resource Name	Reference
Pharos	CHEMBL1235979
PubChem	46942379
ChEMBL	CHEMBL1235979

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.